#inavolisib

@seldon-dengyue.bsky.social

1 month ago

🧬 Nuevo avance en cáncer de mama HR+/HER2−
#Inavolisib + palbociclib + fulvestrant
👉 Para pacientes con #MutaciónPIK3CA

📎 Más información: dengyuepharma.com/product/itov...

📧 info@dengyuemed.com
#Itovebi #CáncerDeMama #CáncerDeMamaAvanzado #Oncología #DengYueMedicinasEnHongKong

GBG

@gbg.de

4 months ago

GeparPiPPa Phase II trial comparing neoadjuvant endocrine therapy in combination with the PI3K-Inhibitor Inavolisib

#GeparPiPPa #GBG105 investigates #neoadjuvant #endocrine therapy in combination with #trastuzumab and #pertuzumab, with or without the #PI3K inhibitor #inavolisib, in patients with HER2-positive, HR-positive, PIK3CA-mutated primary breast cancer.
Learn more about the study www.gbg.de/en/trials/ge...

GBG

@gbg.de

7 months ago

Shifting First-Line Strategy: Inavolisib Shows OS, PFS Gains in INAVO120 Trial | Docwire News INAVO120 shows OS benefit with inavolisib in PIK3CA-mutated HR+/HER2– aBC, raising new considerations for first-line care.

#INAVO120: Neue Hoffnung für Patientinnen mit #PIK3CA-mutiertem HR+/HER2- Brustkrebs! Auf dem #ASCO2025 stellte Prof. Sibylle Loibl die finale OS-Analyse vor: +7 Monate medianes Überleben mit #Inavolisib + #Palbociclib + #Fulvestrant in der First-Line-Therapie
www.docwirenews.com/post/shiftin...

TRAstonDrs

@castltrastondrs.bsky.social

8 months ago

#Medsky🧪 #pharmasky #oncosky #inavolisib + #palbociclib–fulvestrant with significant overall survival benefit, vs placebo+ pfulvestrant. Hyperglycemia, stomatitis or mucosal inflammation, gastrointestinal toxic effects, ocular side effects were reported more frequently with #inavolisib vs placebo.

Oncology Brothers

@oncbrothers.bsky.social

1 year ago

#SABCS24 Day 1 Highlights #CommunityOnc:

1. @FDAOncology Reviews recent approvals: #Ribociclib & #Inavolisib

2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L

3. #DB06: HR+ TDXd

4. #KN522: biomarker analysis

#OncSky #CanSky @sabcs.bsky.social @drsarahsammons.bsky.social @dr-rshatsky.bsky.social

1/5

Oncology Brothers

@oncbrothers.bsky.social

1 year ago

#SABCS23 late breaking abstract to FDA approval: #Inavolisib based off #INAVO120 we 🗣️ design, findings, and AEs/management w/ Dr. Komal Jhaveri!

Full Discussion:
- Oncbrothers.com/inavo120
- Also on the “Oncology Brothers” podcast

#OncSky #MedSky #bcsm #BreastCancer #SABCS24